Table 2. Minimum Inhibitory Concentration data and antimicrobial susceptibility of Gram-negative bacteria from ESKAPE group.
| Drug class | AB |
Klebsiella pneumoniae n = 32 |
Enterobacter spp n = 18 |
Acinetobacter baumannii n = 39 |
Pseudomonas aeruginosa n = 26 |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC (μ g/ml) | MIC 50 | MIC 90 | MIC (μ g/ml) | MIC 50 | MIC 90 | MIC (μ g/ml) | MIC 50 | MIC 90 | MIC (μ g/ml) | MIC 50 | MIC 90 | ||||||||||
| S | I | R | μ g/ml | μ g/ml | S | I | R | μ g/ml | μ g/ml | S | I | R | μ g/ml | μ g/ml | S | I | R | μ g/ml | μ g/ml | ||
| combination agents | SAM | 5/32 15.6% |
2/32 6.3% |
25/32 78.1% |
≥32 | ≥32 | IR | IR | IR | IR | IR | 0 | 3/3 7.7% |
36/39 92.3% |
≥64/32 | ≥64/32 | IR | IR | IR | IR | IR |
| TZP | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 0 | 0 | 39/39 100% |
≥128/4 | ≥128/4 | ND | ND | ND | ND | ND | |
| Cephems | FEP | 21/32 65.6% |
4/32 12.5% |
7/32 21.9% |
2 | ≥64 | 12/18 66.7% |
0 | 6/18 33.3% |
1 | ≥64 | 0 | 0 | 39/39 100% |
≥64 | ≥64 | 19/26 73% |
2/26 7.7% |
5/26 19.2% |
2 | ≥64 |
| CTX | 5/32 16.6% |
0 | 27/32 84.4% |
≥64 | ≥64 | 8/18 44.4% |
0 | 10/18 55.6% |
8 | ≥64 | 0 | 0 | 39/39 100% |
≥64 | ≥64 | IR | IR | IR | IR | IR | |
| CRO | 5/32 16.6% |
0 | 27/32 84.4% |
≥64 | ≥64 | 8/18 44.4% |
0 | 10/18 55.6% |
8 | ≥64 | 0 | 1/39 2.6% |
38/39 97.4% |
≥64 | ≥64 | IR | IR | IR | IR | IR | |
| CFX | 5/32 16.6% |
0 | 27/32 84.4% |
≥64 | ≥64 | 3/18 16.7% |
5/18 27.7% |
10/18 55.6% |
32 | ≥64 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| CAZ | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 0 | 0 | 39/39 100% |
≥64 | ≥64 | 19/26 73% |
2/26 7.7% |
5/26 19.2% |
4 | ≥64 | |
| Carbapenems | ETP | 30/32 93.8% |
0 | 2/32 6.2% |
0.5 | 0.5 | 15/18 83.3% |
1/18 5.6% |
2/18 11.1% |
0.5 | 1 | NA | NA | NA | NA | NA | IR | IR | IR | IR | IR |
| DOR | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 0 | 0 | 39/39 100% |
≥8 | ≥8 | ND | ND | ND | ND | ND | |
| IPM | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 0 | 0 | 39/39 100% |
≥16 | ≥16 | ND | ND | ND | ND | ND | |
| MEM | 30/32 93.8% |
0 | 2/32 6.2% |
0.25 | 0.25 | 17/18 94.4% |
0 | 1/18 5.6% |
≤0.25 | ≤0.25 | 0 | 0 | 39/39 100% |
≥16 | ≥16 | 17/25 68% |
3/25 12% |
5/25 20% |
1 | ≥16 | |
| Lipopetides | COL | 0 | 12/32 37.5% |
20/32 62.5% |
8 | 32 | 0 | 10/18 55.6% |
8/18 44.4% |
2 | 32 | 0 | 29/39 74.4% |
10/39 26.6% |
2 | 8 | 0 | 23/26 88.5% |
3/26 11.5% |
1 | 4 |
| Aminoglycosides | GEN | 17/32 53.1% |
0 | 15/32 46.9% |
≤1 | 16 | 14/18 77.7% |
0 | 4/18 22.2% |
≤1 | ≥16 | 0 | 6/39 15.4% |
33/39 84.6 |
≥16 | ≥16 | 21/26 80.8% |
0 | 5/26 19.2% |
2 | ≥16 |
| AMK | 30/32 93.8% |
0 | 2/32 6.2% |
2 | 8 | 16/18 88.9% |
1/18 5.6% |
1/18 55.6% |
≤2 | 16 | ND | ND | ND | ND | ND | 23/26 88.5% |
0 | 3/26 11.5% |
≤2 | ≥64 | |
| Quinolones | CIP | 8/32 25% |
3/32 9.4% |
21/32 65.6%- |
≥4 | ≥4 | 12/18 66.7% |
0 | 5/18 27.8% |
≤0.25 | ≥2 | 0 | 0 | 39/39 100% |
≥4 | ≥4 | 20/26 77% |
0 | 6/26 23% |
≤0.25 | ≥4 |
Notes.
- AB
- antibiotic
- MIC
- Minimum Inhibitory Concentration
- I
- intermediate susceptibility
- R
- resistant
- S
- susceptible
- SAM
- ampicillin-sulbactam
- TZP
- piperacillin/tazobactam
- FEP
- cefepime
- CTX
- cefotaxime
- CRO
- ceftriaxone
- CFX
- cefuroxime
- CAZ
- ceftazidime
- ETP
- ertapenem
- DOR
- doripenem
- IPM
- imipenem
- MEM
- meropenem
- COL
- colistin
- GEN
- gentamicin
- AMK
- amikacin
- CIP
- ciprofloxacin
- IR
- íntrinsic resistance
- ND
- not determined
- NA
- Does not